Lord, Abbett & Co
TARS icon

Lord, Abbett & Co’s Tarsus Pharmaceuticals TARS Stock Holding History

Lord, Abbett & Co’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.2M Sell
479,266
-363,047
-43% -$23.2M 0.09% 251
2026
Q1 		$59.1M Sell
842,313
-13,332
-2% -$932K 0.19% 141
2025
Q4 		$70.1M Sell
855,645
-129,984
-13% -$9.71M 0.21% 124
2025
Q3 		$58.6M Sell
985,629
-9,796
-1% -$482K 0.17% 147
2025
Q2 		$40.3M Sell
995,425
-336,276
-25% -$15.1M 0.13% 185
2025
Q1 		$68.4M Buy
1,331,701
+51,714
+4% +$2.56M 0.24% 114
2024
Q4 		$70.9M Buy
1,279,987
+685,111
+115% +$31.1M 0.22% 122
2024
Q3 		$19.6M Buy
594,876
+131,636
+28% +$3.7M 0.06% 333
2024
Q2 		$12.6M Buy
463,240
+381,014
+463% +$12.8M 0.04% 369
2024
Q1 		$2.99M Buy
+82,226
New +$2.42M 0.01% 510

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Lord, Abbett & Co's TARS Position: Q2 2026 in Review

Lord, Abbett & Co reduced its Tarsus Pharmaceuticals (TARS) stake by 43% in Q2 2026, selling an estimated $23.2M and leaving 479,266 shares worth $30.2M. The position accounts for 0.09% of the portfolio, ranked #251.

Lord, Abbett & Co first reported a position in TARS in Q1 2024 and has held it in 10 quarters since. The position peaked at $70.9M in Q4 2024. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Lord, Abbett & Co held 479,266 shares of Tarsus Pharmaceuticals worth $30.2M as of Q2 2026.
  • Lord, Abbett & Co sold 363,047 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $23.2M.
  • Tarsus Pharmaceuticals made up 0.09% of Lord, Abbett & Co's portfolio in Q2 2026, its #251 holding.
  • Lord, Abbett & Co first reported a position in Tarsus Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Lord, Abbett & Co's Tarsus Pharmaceuticals position peaked at $70.9M in Q4 2024.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Lord, Abbett & Co's 13F filing for Q2 2026, filed 14 Aug 2026.